Evidence map›Paper›PMID 41982273›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026

A Jehovah's Witness with Acquired Hemophilia A Who Successfully Avoided Blood Transfusions by Receiving Emicizumab.

Makoto Saito, Atsushi Yasumoto, Masahiro Ieko, Naoki Miyashita, Emi Yokoyama, Minoru Kanaya, Koh Izumiyama, Akio Mori, Masanobu Morioka, Takeshi Kondo

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Makoto SaitoBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Atsushi YasumotoDepartment of Hematology, Hokkaido University, Faculty of Medicine, Graduate School of Medicine, Sapporo, Japan.
Masahiro IekoDepartment of Nursing, Faculty of Health and Medical Sciences, Sapporo University of Health Sciences, Sapporo, Japan.
Naoki MiyashitaBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Emi YokoyamaBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Minoru KanayaBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Koh IzumiyamaBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Akio MoriBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Masanobu MoriokaBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Takeshi KondoBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Acquired hemophilia A (AHA) manifests as a significant deficiency in coagulation factor VIII (FVIII) activity caused by the development of autoantibodies against FVIII and results in severe bleeding symptoms that can be life-threatening. Therefore, patients with AHA often require blood transfusions. Emicizumab, a bispecific monoclonal antibody that replaces the function of activated FVIII, has been more widely used to treat AHA. Case Presentation: We report a 70-year-old male Jehovah's Witness with AHA who refused blood transfusions despite experiencing severe bleeding in the left biceps muscle; anemia had progressed by 3 g/dL (hemoglobin level) in just 2 days. Since the use of coagulation factor products had been approved in writing, we administered a single-dose mixture of activated factor VIIa/X (Byclot®) and promptly achieved hemostasis. Subsequently, regular administration of emicizumab was effective in preventing rebleeding and successfully avoiding blood transfusions. Conclusion: For Jehovah's Witnesses with AHA, the administration of emicizumab can be considered a highly valuable treatment.

Indexed as

Acquired hemophilia ABlood transfusionsEmicizumabFactor VIIa and X mixturesJehovah’s Witness

Identifiers

PMID41982273
PMCPMC13075870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.